Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
6 search results for:

BLU-667 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 13-06-2019 | Non-small-cell lung cancer | News | Article

    BLU-667 active against RET fusion-positive advanced NSCLC

    Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.

    Published in:
    2019 ASCO Annual Meeting; Chicago, Illinois, USA: 31 May–4 June
  2. 30-09-2021 | EMA | News | Article
    approvalsWatch

    Pralsetinib receives nod from EMA for use in RET-positive NSCLC

    This decision by the EMA’s Committee for Medicinal Products for Human Use follows positive findings of the RET receptor tyrosine kinase inhibitor (previously known as BLU-667) in this patient population in the pivotal phase 1/2 ARROW study .

    Author:
    Hannah Kitt
  3. 19-04-2018 | Medullary thyroid carcinoma | News | Article

    Targeted inhibitor shows potential for RET-altered solid tumors

    BLU-667 also has “favorable tolerability,” he added.

    Published in:
    AACR 2018; Chicago, Illinois, USA
  4. 30-04-2018 | RET inhibitors | News | Article

    More evidence for selective RET inhibition in RET-altered cancers

    BLU-667 showed promising activity in the trial, with 18 of 40 evaluable patients achieving an objective response at data cutoff.

    Published in:
    Ann Oncol 2018; Advance online publication
  5. 18-09-2020 | FDA | News | Article
    approvalsWatch

    Pralsetinib gets FDA go-ahead for RET fusion-positive lung cancer

    Click through to read more

    Author:
    Lynda Williams
  6. 01-06-2019 | Lung cancer | Video | Article

    Expert highlights: Lung cancer at ASCO 2019

    Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

    Published in:
    2019 ASCO Annual Meeting; Chicago, Illinois, USA: 31 May–4 June
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.